ACM
OVID icon

ADAR1 Capital Management’s Ovid Therapeutics OVID Stock Holding History

ADAR1 Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20M Buy
7,417,479
+2,873,366
+63% +$7.41M 0.91% 23
2026
Q1 		$10.1M Buy
4,544,113
+259,113
+6% +$463K 0.59% 45
2025
Q4 		$6.98M Buy
4,285,000
+4,272,154
+33,257% +$6.58M 0.51% 43
2025
Q3 		$16.7K Sell
12,846
-103,021
-89% -$89.3K ﹤0.01% 216
2025
Q2 		$38.2K Hold
115,867
– – 0.01% 194
2025
Q1 		$36.1K Sell
115,867
-14,665
-11% -$9.02K 0.01% 184
2024
Q4 		$122K Buy
130,532
+92,789
+246% +$104K 0.02% 175
2024
Q3 		$44.5K Buy
37,743
+18,553
+97% +$19.4K 0.01% 221
2024
Q2 		$14.8K Buy
19,190
+2,744
+17% +$7.64K ﹤0.01% 228
2024
Q1 		$50.2K Buy
16,446
+3,200
+24% +$10.7K 0.01% 179
2023
Q4 		$42.7K Buy
+13,246
New +$45.3K 0.02% 120

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

ADAR1 Capital Management's OVID Position: Q2 2026 in Review

ADAR1 Capital Management increased its Ovid Therapeutics (OVID) stake by 63% in Q2 2026, buying an estimated $7.41M and bringing the position to 7,417,479 shares worth $20M. The position accounts for 0.91% of the portfolio, ranked #23.

ADAR1 Capital Management first reported a position in OVID in Q4 2023 and has held it in 11 quarters since. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • ADAR1 Capital Management held 7,417,479 shares of Ovid Therapeutics worth $20M as of Q2 2026.
  • ADAR1 Capital Management bought 2,873,366 Ovid Therapeutics shares in Q2 2026, an estimated $7.41M.
  • Ovid Therapeutics made up 0.91% of ADAR1 Capital Management's portfolio in Q2 2026, its #23 holding.
  • ADAR1 Capital Management first reported a position in Ovid Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.